The study, published in BioMed Central's open access journal Molecular Neurodegeneration, found that neurons in the brain were protected after treatment with T-type calcium-channel blockers, which are commonly used to treat epilepsy.
Calcium signaling pathways play a vital role in the survival of neurons in the brain. As age increases, calcium homeostasis can be disrupted in the brain, which may lead to cognitive and functional decline. It therefore raises the possibility that chemicals able to modulate calcium homeostasis could protect neurons.
Jianxin Bao and colleagues, from Washington University, Missouri, USA, were one of the first teams to explore the possible protective effects of blockers for T-type calcium channels. The mechanisms for neuroprotection by these antiepileptic drugs were previously unknown. Bao's team established cell culture models to directly test whether these drugs could preserve neurons in long- and short-term cultures in vitro.
They found that neurons showed an increase in viability after treatment with either L-type or T-type calcium channel inhibitors. Furthermore, neurons in the long-term and short-term cultures were protected, respectively, by L-type and T-type calcium channel blockers, suggesting that more than one calcium-signaling mechanism exists to regulate long- and short-term neuron survival.
There are presently no effective medications for age-related neurodegeneration. Bao said "Our data provides implications for the use of this family of anti-epileptic drugs in developing new treatments for neuronal injury, and for the need of further studies of the use of such drugs in age-related neurodegenerative disorders."
1. Neuroprotective effects of blockers for T-type calcium channels
Norelle C Wildburger, Avary Lin-Ye, Michelle A Baird, Debin Lei and Jianxin Bao
Molecular Neurodegeneration (in press)
2. Molecular Neurodegeneration is an open access, peer-reviewed online journal that will encompass all aspects of neurodegeneration research at the molecular and cellular levels.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
Charlotte Webber | Source: EurekAlert!
Further information: www.biomedcentral.com
Further Reports about: BioMed > calcium channel > Epilepsy > L-type > Molecular Target > neurodegenerative disorder > signaling pathway > STM > T-type
More articles from Studies and Analyses:
Daycare may double TV time for young children
24.11.2009 | Seattle Children's
Insomnia prevalent among cancer patients who receive chemotherapy
24.11.2009 | University of Rochester Medical Center
Daycare may double TV time for young children
24.11.2009 | Studies and Analyses
Insomnia prevalent among cancer patients who receive chemotherapy
24.11.2009 | Studies and Analyses
24.11.2009 | Social Sciences
Multidisciplinary meeting on Urological Cancers aims to benefit cancer patients
20.11.2009 | Event News
'Golden Age' for clinical psychology in Northern Ireland
20.11.2009 | Event News
New Perspectives in Marine Anti-Fouling Research
11.11.2009 | Event News